Certuity LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Certuity LLC significantly reduced its stake in Regeneron Pharmaceuticals Inc. by 70.7% in Q4, selling 1,536 shares and leaving 637 shares valued at approximately $492,000. Despite this, Regeneron exceeded Q4 earnings expectations with an EPS of $11.44 and revenue of $3.88 billion, and increased its quarterly dividend. The stock maintains a “Moderate Buy” consensus rating with an average target price of $825.35.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments